Basilea Raises FY26 Income Guidance to CHF 250M, Lifts 2030 Cash Target
Basilea raised FY26 guidance for Cresemba- and Zevtera-related income to CHF 250M, 19% above its prior guidance, and increased its cumulative cash flow target through 2030 to CHF 650M. The company also outlined streamlined plans for ceftibuten-ledaborbactam and reported progress in fosmanogepix Phase 3.